In the treatment of neoplastic diseases, the therapeutic use of folate antagonists such as methotrexate is often accompanied by the concurrent or subsequent administration of 5-formyltetrahydrofolate (folinic acid, leucovorin) in order to reverse its effects (Mead et al., 1963; Hryniuk and Bertino, 1969) .
In vitro, this reduced folate is readily altered by acid conditions (May et al., 1951) such as may exist in the stomach, and it has, therefore, been administered parenterally. It has been recognized for some time (Nixon and Bertino, 1972 ) that an effective, orally administered, reduced folate would have a useful place in the increasing use of cancer chemotherapy, and effective absorption of oral doses up to 1 mg has been demonstrated (Chanarin, 1969; Nixon and Bertino, 1972) . Such doses are small compared to those employed therapeutically (often greater than 20 mg) and further evidence of acceptable absorption in this dose range would be desirable.
Each of three pairs of healthy Caucasian male volunteers (Table) were ran- Folinic acid concentrations were estimated using the growth response of Lactobacillus casei, which responds to most folic acid derivatives, including folinic acid and 5-methyltetrahydrofolate. Much of the folinic acid will be converted to the 5-methyl form by the intestinal mucosa (Whitehead, et. al. 1972 ). The procedure adopted was a modification of that employed by Herbert (1961) and used in the routine haematology laboratory for the measurement of serum folate. In this experiment, except for the initial samples, serum was diluted x 100, using phosphate buffer with 1% ascorbic acid, to bring the results within the reliable range of the assay procedure.
All subjects had normal serum folate levels at the start of the experiment.
The mean folinic acid concentrations found in each group of subjects are shown in the Fig. together to that following i.m. injection, subsequent concentrations were higher in the oral group.
Assuming a similar rate of blood clearance of the drug (via the kidneys and into the body stores), the area under each curve will be related to the total quantity of folinic acid absorbed. The area under the i.m. curve is 2485 units; that under the oral curve is 2328 units. The difference between these two areas is 6-3%, and inspection of the graph suggests that if the time period of measurement had been extended the difference would have been smaller.
It is possible that high doses of methotrexate may impair the absorption of folinic acid by the intestinal mucosa. We have found that the bioassay system employed to measure serum folate does not produce reliable results, using serum from patients who have received a high dose of methotrexate (200 mg by i.v. infusion over 24 h). However, Whitehead et al. (1972) have shown that, after 2 mg of oral folinic acid, a proportion is absorbed directly into the blood without metabolism by the intestinal mucosa. Any blockage of folinic acid metabolism at that site may thus be bypassed by a much more extensive direct absorption from a large dose. Hoffbrand and Fry (1972) , using the urinary excretion test, measured the absorption of orally administered tritiumlabelled folic acid in patients who had or had not received 25 mg of methotrexate. They found that the methotrexate did not seem to affect the quantity of folate absorbed. This underlines a clinical impression in several centres that patients who have been given oral folinic acid empirically after methotrexate therapy have fared as well as when receiving it parenterally.
In these circumstances, the relatively small differences between the blood levels reached after oral and i.m. administration, which we have demonstrated above, suggest that satisfactory absorption of folinic acid occurs after large, oral doses and that it may, therefore, be possible to avoid the parenteral route.
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